Basal cell carcinoma (BCC) is a common cancer in the world.
It is also known as aggressive ulcer
.
Basal cell carcinoma is more common in the elderly, and it is more common in the head, face, neck and back of the hands, especially the prominent parts of the face
.
It is closely related to sunlight
.
In the past, researchers used molecular data of human basal cell carcinoma to screen for drug location and determined that histone deacetylase (HDAC) inhibitors are a potential treatment for basal cell carcinoma
.
This study aims to explore the activity of an HDAC inhibitor, Remetinostat, in the treatment of base cell carcinoma
.
This is an open-label, single-center Phase II trial that recruits patients with basal cell carcinoma
.
All subjects were treated with 1% Remetinostat gel 3 times a day for 6 weeks; tumor diameters were measured at baseline and 8 weeks
.
At the end of the study, the residual tumor was surgically removed and observed under a microscope
.
Change in tumor diameter at the 8th week
Change in tumor diameter at the 8th week33 tumors from 25 patients were included in the analysis
.
Remission definition: The maximum tumor diameter at week 8 was reduced by more than 30% from baseline, and the overall response rate was 69.
7% (90 CI 54-82.
5%)
.
Pathological examination showed that 54.
8% of tumors completely resolved
.
7% The overall response rate was 69.
7% 54.
8% The tumor completely resolved 54.
8% The tumor completely resolved
Pathological changes before and after treatment
Pathological changes before and after treatmentPharmacodynamic analysis showed that the level of acetylated histone H3 in the skin tissues before and after treatment was similar, but the phosphorylation level was increased
.
No systemic adverse events were reported
.
All in all, the HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce the disease burden of basal cell carcinoma
.
This study provides human verification for the use of HDAC inhibitors for the treatment of base cell carcinoma
.
The HDAC inhibitor Remetinostat is a well-tolerated and effective local treatment drug that can significantly reduce basal cells.
Burden of cancer
Original source:
Original source:James M.
Kilgour, et al.
Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma .
Clin Cancer Res September 1 2021 27 (17) 4717-4725; DOI :10.
1158/1078-0432.
CCR-21-0560
in this message
